HEMOSTEMIX ANNOUNCES PETER LACEY AS CHAIRMAN OF THE BOARD OF DIRECTORSMarch 19, 2020
Calgary, Alberta, March 19, 2020 – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce the election of Mr. Peter Lacey, ICD.D as Chairman of its Board of Directors.
Peter Lacey is currently the Chairman of Cervus Equipment Corporation (CERV.TO), a company he and his partners started in 1999 and built from five John Deere dealerships into a company that owns 63 dealerships selling six brands in three countries with revenues of $1.1 Billion, paying a quarterly dividend of $0.11 per share. Mr. Lacey has been Chairman of Cervus Equipment since inception, and was President and Chief Executive Officer of Cervus Equipment Corporation and its predecessor entities from 1982 to April 2012. Mr. Lacey is a graduate of the Institute of Corporate Directors Education Program at the University of Toronto.
“Nominating Peter to the board of directors and electing him as its Chairman is a significant milestone for the Company, said Thomas Smeenk, President. “Our team greatly appreciates Peter’s business acumen, global company build-experience and leadership reputation for ethical business dealings, trust, transparency, and straightforwardness. I look forward to working with him, together with the board of directors, to incorporate the board’s strategic guidance into our commercialization and growth execution plan,” Smeenk said.
“As a significant, long term investor in Hemostemix, I am pleased to be asked to join the Board and be elected as its Chairman. Hemostemix and its patented technology offer significant potential to help thousands of patients globally with various conditions of ischemia and reducing potential loss of limbs. Successful execution of commercializing this technology to bring significant shareholder value will be our prime objective,” said Mr. Lacey.
Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.
On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.
The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit www.hemostemix.com.
Contact: Thomas Smeenk, President, CEO & Founder
Suite 1150, 707 – 7th Avenue S.W., Calgary, Alberta T2P 3H6, 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” and similar expressions, or that events or conditions “will,” “would,” “may,” “could,” or “should” occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. By their nature forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to fund operations and access the capital required to continue operations, the Company’s stage of development, the ability to complete its current CLI clinical trial, complete a futility analysis and the results of such, future clinical trials and results, long-term capital requirements and future developments in the Company’s markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the Company’s operations. Each factor should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. Additional information identifying risks and uncertainties are contained in the Company’s filing with the Canadian securities regulators, which filings are available at www.sedar.com.
View All News & Media